Canadian Cannabis Copacking Group Ltd., a packaging technology services company, has recently formed a joint venture for the purposes of contract manufacturing and copacking services for dry flower and pre-roll production.

The joint venture is registered as Craft Cannabis Copacking Services Ltd. (C3) and is fully operational as of April 1st, 2022, for production runs in bottles both glass and plastic and flexible packaging (child-proof bags) plus pre-rolls in various configurations. The fully licensed facility is located in Nisku, Alberta and will service Western Canada in 2022 and nationally in 2023.

Hygrovest has funds available to deploy in new investments and will also seek to realise existing investments to recycle capital into opportunities having greater potential for growth.

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab's products and to assist Canntab in reaching strategic partnerships in the Cannabis industry with a view to enhancing shareholder value.

“When you have your brand promise anchored in quality, you don’t need celebrity endorsements and billboards.”

Xebra Brands Ltd. ("Xebra") (CSE: XBRA) (OTCQB: XBRAF) (FSE: 9YC), a cannabis company, is pleased to announce that its Vicious Citrous cannabis infused lemonade, has been accepted by the Ontario Cannabis Store (OCS), for listing and sale in the Province of Ontario, Canada.

Vicious Citrus Lemonade combines 10mg of THC with 2mg of CBN (Cannabinol).  Vicious Citrus is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America. At the following link an article on CBN published by MJBizDaily:

A Southwestern Ontario pot producer that bills itself as Canada’s first female-focused cannabis company filed for creditor protection as it faces a “critical cash shortage.”

An Ontario court has approved a request by Eve and Co., a licensed cannabis grower that operates a massive greenhouse in Strathroy, to sell assets and seek investment after it was granted protection under the Companies’ Creditors Arrangement Act (CCAA).

“The creditor protection is kind of a temporary holding status,” said Michael Armstrong, a professor at Brock University’s Goodman school of business who studies the cannabis industry.

Canada’s #1 Cannabis Event returns May 12-15, 2022, revealing what’s next in Canada and across the globe, as well as plenty of F-U-N!

Tickets are on sale now for Lift&Co. Expo, Canada’s no. 1 cannabis conference and trade show, taking place at the Metro Toronto Convention Centre, May 12-15, 2022. As the highly anticipated show draws near, the team behind the scenes reveals noteworthy new features and a schedule of can’t-miss content to power the future of Canada’s booming cannabis industry.

 Lift&Co. Expo Toronto 2022 includes:​

When will Canadian cannabis companies be allowed to tap into the US marketplace?

As chatter about cannabis legalization below the border heats up, when will Canadian producers be able to tap into the opportunity in the booming US marketplace?

Operators in Canada have for the most part fallen out of favor, thanks in large part to poor financial results and a clear ceiling on what the domestic market can offer — especially compared to opportunities for US stocks.

While Canadian companies have targets in their sights and are talking about what their plays in the US could be, experts are cautioning market participants about the realities of the market.

Germany’s impending legalization of recreational marijuana offers attractive new opportunities for travel, trade and investment, according to a recent survey of American cannabis consumers. The survey from medical marijuana holding company Bloomwell Group found that eight out of 10 Americans believe that “cannabis companies are attractive investment options,” while 61% said that they “would invest in European cannabis stocks.”

Jefferies lowered their price target on Tilray Brands (TSX: TLRY), after updating their outlook, saying excluding all the Canadian headwinds, the overall outlook looks compelling. Jefferies lowered their 12-month price target from $17.00 to $15.60 and reiterated its buy rating on the stock.

Tilray currently has 20 analysts covering the stock with an average 12-month price target of US$8.47, or a 33% upside to the current stock price. Out of the 20 analysts, 2 have strong buy ratings, 2 have buy ratings, 13 analysts have hold ratings and the last 3 have sell ratings. The street high sits at US$23, which represents a 260% upside to the stock.